Mina Nikanjam

Title(s)Associate Physician Diplomate, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Optimizing Dolutegravir Initiation in Neonates using Population Pharmacokinetic Modeling and Simulation. J Acquir Immune Defic Syndr. 2021 Oct 06. Piscitelli J, Nikanjam M, Best BM, Acosta E, Mirochnick M, Clarke DF, Capparelli EV, Momper JD. PMID: 34629412.
      View in: PubMed   Mentions:    Fields:    
    2. Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. Genome Med. 2021 Oct 04; 13(1):155. Sicklick JK, Kato S, Okamura R, Patel H, Nikanjam M, Fanta PT, Hahn ME, De P, Williams C, Guido J, Solomon BM, McKay RR, Krie A, Boles SG, Ross JS, Lee JJ, Leyland-Jones B, Lippman SM, Kurzrock R. PMID: 34607609; PMCID: PMC8491393.
      View in: PubMed   Mentions:    Fields:    
    3. S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults. Eur J Clin Pharmacol. 2021 Sep; 77(9):1349-1356. Tran L, Nikanjam M, Capparelli EV, Bertino JS, Nafziger AN, Kashuba ADM, Turpault S, Ma JD. PMID: 33754183.
      View in: PubMed   Mentions:    Fields:    
    4. BRAF V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. Mol Cancer Ther. 2021 06; 20(6):1072-1079. Nikanjam M, Tinajero J, Barkauskas DA, Kurzrock R. PMID: 33722853.
      View in: PubMed   Mentions:    Fields:    
    5. Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. EJNMMI Res. 2020 Dec 09; 10(1):150. Haghighat Jahromi A, Barkauskas DA, Zabel M, Goodman AM, Frampton G, Nikanjam M, Hoh CK, Kurzrock R. PMID: 33296034.
      View in: PubMed   Mentions: 2  
    6. Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. Clin Pharmacol Ther. 2021 01; 109(1):184-192. Li J, Nikanjam M, Cunningham CK, McFarland EJ, Coates EE, Houser KV, Lin BC, McDermott AB, Flach B, Gama L, Koup RA, Graham BS, Mascola JR, Ledgerwood JE, Capparelli EV. PMID: 32866318.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    7. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020 10 02; 11(1):4965. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 33009371.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    8. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Mol Oncol. 2021 01; 15(1):67-79. Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT, Kurzrock R. PMID: 32881280.
      View in: PubMed   Mentions: 3     Fields:    
    9. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy. Cureus. 2020 Jul 02; 12(7):e8967. Cohen PR, Nikanjam M, Kato S, Goodman AM, Kurzrock R. PMID: 32766009.
      View in: PubMed   Mentions:
    10. Tumor mutational burden is not predictive of cytotoxic chemotherapy response. Oncoimmunology. 2020 06 24; 9(1):1781997. Nikanjam M, Riviere P, Goodman A, Barkauskas DA, Frampton G, Kurzrock R. PMID: 32923144.
      View in: PubMed   Mentions: 1  Translation:Humans
    11. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev. 2020 Jun; 86:102019. Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. PMID: 32251926.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    12. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology. 2020; 9(1):1708065. Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R. PMID: 32117584.
      View in: PubMed   Mentions: 10  Translation:HumansCells
    13. Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. Oncoimmunology. 2020; 9(1):1710052. Jardim DL, De Melo Gagliato D, Nikanjam M, Barkauskas DA, Kurzrock R. PMID: 32002305.
      View in: PubMed   Mentions: 4  Translation:Humans
    14. Development and preclinical pharmacology of a novel dCK inhibitor, DI-87. Biochem Pharmacol. 2020 02; 172:113742. Poddar S, Capparelli EV, Rosser EW, Gipson RM, Wei L, Le T, Jung ME, Radu C, Nikanjam M. PMID: 31812677.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    15. Targeting fusions for improved outcomes in oncology treatment. Cancer. 2020 03 15; 126(6):1315-1321. Nikanjam M, Okamura R, Barkauskas DA, Kurzrock R. PMID: 31794076.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol. 2019 12; 84(6):1339-1348. Kawakatsu S, Nikanjam M, Lin M, Le S, Saunders I, Kuo DJ, Capparelli EV. PMID: 31586225.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    17. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. Int J Cancer. 2020 06 01; 146(11):3087-3097. Nikanjam M, Arguello D, Gatalica Z, Swensen J, Barkauskas DA, Kurzrock R. PMID: 31479512.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    18. Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. Ann Oncol. 2019 10 01; 30(10):1675. Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R. PMID: 31408092.
      View in: PubMed   Mentions: 2     Fields:    
    19. Population pharmacokinetics of siltuximab: impact of disease state. Cancer Chemother Pharmacol. 2019 11; 84(5):993-1001. Nikanjam M, Yang J, Capparelli EV. PMID: 31482226.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    20. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults. J Clin Pharmacol. 2019 11; 59(11):1495-1504. Yang J, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Stoch SA, Bertino JS, Nafziger AN, Ma JD. PMID: 31051051.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults. Ther Drug Monit. 2018 12; 40(6):754-758. Lin S, Nikanjam M, Capparelli EV, Allegrini A, Pavone D, Yim DS, Hammami MM, Bertino JS, Nafziger AN, Park YS, Kang JS, Yin OQ, Ma JD. PMID: 30045358.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience. Cureus. 2018 Nov 26; 10(11):e3634. Nikanjam M, Wing J, Capparelli E, Kurzrock R. PMID: 30705793.
      View in: PubMed   Mentions:
    23. Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. Ann Oncol. 2018 11 01; 29(11):2192-2199. Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R. PMID: 30219896.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    24. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. J Clin Pharmacol. 2018 12; 58(12):1604-1617. Yang J, Nikanjam M, Best BM, Pinto J, Chadwick EG, Daar ES, Havens PL, Rakhmanina N, Capparelli EV. PMID: 30252146.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    25. Vincristine-associated Neuropathy With Antifungal Usage: A Kaiser Northern California Experience. J Pediatr Hematol Oncol. 2018 07; 40(5):e273-e277. Nikanjam M, Sun A, Albers M, Mangalindin K, Song E, Vempaty H, Sam D, Capparelli EV. PMID: 29771861.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    26. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach. J Clin Pharmacol. 2018 09; 58(9):1205-1213. Yang J, Patel M, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Aubrey Stoch S, Bertino JS, Nafziger AN, Ma JD. PMID: 29663428.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    27. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemother Pharmacol. 2018 01; 81(1):171-178. Nikanjam M, Capparelli EV, Lancet JE, Louie A, Schiller G. PMID: 29167924.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    28. ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. Nat Commun. 2017 08 14; 8(1):241. Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblum HI, Ribas A, Herschman HR, Whitelegge J, Faull KF, Donahue TR, Czernin J, Radu CG. PMID: 28808226.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    29. Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. Oncoimmunology. 2017; 6(8):e1338997. Hanna RF, Ward TJ, Chow DS, Lagana SM, Moreira RK, Emond JC, Weintraub JL, Prince MR, Nikanjam M, Patel H, Kurzrock R. PMID: 28920006; PMCID: PMC5593707.
      View in: PubMed   Mentions: 13  
    30. Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. Oncologist. 2017 05; 22(5):576-584. Nikanjam M, Liu S, Yang J, Kurzrock R. PMID: 28424323.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    31. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. Int J Cancer. 2016 Nov 01; 139(9):2135-41. Nikanjam M, Liu S, Kurzrock R. PMID: 27389805.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    32. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget. 2016 Mar 08; 7(10):11310-20. Liu S, Nikanjam M, Kurzrock R. PMID: 26824502.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    33. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemother Pharmacol. 2015 Mar; 75(3):495-503. Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV. PMID: 25557868.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    34. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother. 2012 Oct; 56(10):5374-80. Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, Spector SA, Capparelli EV. PMID: 22869579.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    35. Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing. Clin Pharmacol Ther. 2012 Feb; 91(2):243-9. Nikanjam M, Chadwick EG, Robbins B, Alvero C, Palumbo P, Yogev R, Pinto J, Hazra R, Hughes ML, Heckman BE, Capparelli EV, IMPAACT P1030 Team . PMID: 22190064.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    36. Developmental pharmacokinetic changes of Lamivudine in infants and children. J Clin Pharmacol. 2012 Dec; 52(12):1824-32. Tremoulet AH, Nikanjam M, Cressey TR, Chokephaibulkit K, McKinney R, Mirochnick M, Capparelli EV. PMID: 22180560.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    37. Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults. Clin Pharmacol Ther. 2009 Apr; 85(4):394-401. Sleasman JW, Robbins BL, Cross SJ, Lindsey JC, Kraimer JM, Heckman BE, Sprenger HL, Tustin NB, Rose CH, Poston PA, Neal EF, Pakes GE, Nikanjam M, Capparelli EV. PMID: 19118380.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    38. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release. 2007 Dec 20; 124(3):163-71. Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. PMID: 17964677.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    39. Finger flexor motor control patterns during active flexion: an in vivo tendon force study. Hum Mov Sci. 2007 Feb; 26(1):1-10. Nikanjam M, Kursa K, Lehman S, Lattanza L, Diao E, Rempel D. PMID: 17173995.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    40. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm. 2007 Jan 02; 328(1):86-94. Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM. PMID: 16959446.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    Mina's Networks
    Concepts (163)
    Derived automatically from this person's publications.
    _
    Co-Authors (40)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _